$9.11
Value $420M
CLB and XOM stock compared: price, dividend, valuation and results, from SEC filings.
$9.11
Value $420M
$170.59
Value $711B
Core Laboratories (CLB) has a market value of $420M and ExxonMobil (XOM) $711B. Over the last year, with dividends, CLB moved -40.8% and XOM +48.6%. The P/E is 27.0 for CLB and 17.5 for XOM. Dividend yield: CLB 0.44%, XOM 2.42%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CLB$420M
XOM$711B
XOM is 1,694 times CLB
Revenue, 12 months
CLB$517M
XOM$397B
XOM is 768 times CLB
Net income, 12 months
CLB$16M
XOM$40.6B
XOM is 2,611 times CLB
Operating margin
CLB7.5%
XOM–
ROIC
CLB8.0%
XOM13.9%
5.9 points apart
P/E
CLB27.0
XOM17.5
CLB is 1.5 times XOM
Dividend yield
CLB0.4%
XOM2.4%
2.0 points apart
5-year return
CLB-64.7%
XOM+214.2%
278.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CLB-64.7%
XOM+214.2%
| Period | CLBWith dividends | XOMWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -40.8%Price -41.0% | +48.6%Price +44.4% |
| 3 years since November 13, 2023 | -51.3%-21.3% a yearPrice -51.7% | +79.5%+21.5% a yearPrice +62.7% |
| 5 years since November 12, 2021 | -64.7%-18.8% a yearPrice -65.1% | +214.2%+25.7% a yearPrice +167.3% |
| 10 years since November 16, 2016 | -90.6%-21.0% a yearPrice -91.4% | +203.9%+11.8% a yearPrice +98.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CLBCore LaboratoriesXOMExxonMobil
| Price | $9.11 | $170.59 |
|---|---|---|
| Market value | $420M | $711B |
| Enterprise value (EV) | $511M | $733B |
| P/E | 27.0 | 17.5 |
| P/E, 5-year median | 26.2 | 11.4 |
| P/B | 1.5 | 2.7 |
| EV/EBIT | 13.1 | 13.2 |
| Free cash flow yield | 2.5% | 6.0% |
| Revenue, 12 months | $517M | $397B |
|---|---|---|
| Net income, 12 months | $16M | $40.6B |
| Free cash flow, 12 months | $10M | $43.0B |
| Earnings per share, 12 months | $0.34 | $9.74 |
| Revenue growth, year on year | 0.5% | -5.0% |
| Revenue growth a year, past | +2.9%over 4 years | +12.9%over 5 years |
| EPS growth a year, past | +10.7%over 4 years | – |
| Gross margin | 19.1% | – |
|---|---|---|
| Operating margin | 7.5% | – |
| Net margin | 3.0% | 10.2% |
| ROIC | 8.0% | 13.9% |
| ROE | 5.7% | 15.6% |
| Cash | $21M | $12.2B |
|---|---|---|
| Total debt | $162M | $34.3B |
| Net debt / EBITDA | 1.7 | 0.3 |
| Interest cover | 3.5× | 64.1× |
| Dividend yield | 0.4% | 2.4% |
|---|---|---|
| Dividend per share, 12 months | $0.04 | $4.12 |
| Dividend growth a year, past | +0.0%over 4 years | +2.8%over 5 years |
| Buyback yield | 3.0% | 2.9% |
| Shareholder yield | 3.4% | 5.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, ExxonMobil ($711B) is about 1,694.3 times Core Laboratories ($420M), at today's prices.
Since November 16, 2016, CLB's price moved -91.4% and XOM's +98.9%. With dividends: CLB -90.6% (-21.0% a year), XOM +203.9% (+11.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.44% for Core Laboratories and 2.42% for ExxonMobil. Over the last twelve months they paid $0.04 and $4.12 per share.
At today's price, the P/E is 27.0 for CLB and 17.5 for XOM. The median of the last five years was 26.2 and 11.4, which shows where each stands against its own past.
Over the last twelve months, the net margin was 3.0% for Core Laboratories and 10.2% for ExxonMobil, and the operating margin 7.5% and –. Revenue was $517M and $397B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.